A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
Supplemental materials for: Uy et al
Files in this Data Supplement:
Document 1. Supplemental methods, tables, and figure (PDF, 606 KB)